The Patent Finder

Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics

E R Squibb and Sons LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/JP2006/309606, filed May 2, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,441,655Monoclonal Antibodies to Programmed Death 1 (PD-1)
In force
 · High confidence
UsedRemaining
E. R. Squibb & Sons, L.L.C.In forceHigh confidence
US 8,779,105Monoclonal Antibodies to Programmed Death 1 (PD-1)
In force
 · High confidence
E. R. Squibb & Sons, L.L.C.In forceHigh confidence
US 8,008,449Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics
In force
 · High confidence
E. R. Squibb & Sons, L.L.C.In forceHigh confidence
US 9,084,776Methods for Treating Cancer Using ANTI-PD-1 Antibodies
Term ended
Term ended May 2, 2026 · High confidence
E. R. Squibb & Sons, L.L.C.Term endedTerm ended May 2, 2026High confidence
US 9,358,289Methods for Treating Cancer Using ANTI-PD-1 Antibodies in Combination with ANTI-CTLA-4 Antibodies
Term ended
Term ended May 2, 2026 · High confidence
E. R. Squibb & Sons, L.L.C.Term endedTerm ended May 2, 2026High confidence
US 9,492,540Methods for Treating Cancer Using ANTI-PD-1 Antibodies
Term ended
Term ended May 2, 2026 · High confidence
E. R. Squibb & Sons, L.L.C.Term endedTerm ended May 2, 2026High confidence
US 9,387,247Monoclonal Antibodies to Programmed Death 1 (PD-1)
Term ended
Term ended Oct 24, 2026 · High confidence
E. R. Squibb & Sons, L.L.C.Term endedTerm ended Oct 24, 2026High confidence
US 9,492,539Monoclonal Antibodies to Programmed Death 1 (PD-1)
Term ended
Term ended Oct 24, 2026 · High confidence
E. R. Squibb & Sons, L.L.C.Term endedTerm ended Oct 24, 2026High confidence
Application 16/600,272Monoclonal Antibodies to Programmed Death 1 (PD-1)
Abandoned
Abandoned Mar 10, 2023
E. R. Squibb & Sons, L.L.C.AbandonedAbandoned Mar 10, 2023
Application 18/167,012Monoclonal Antibodies to Programmed Death 1 (PD-1)
Abandoned
Abandoned Jun 23, 2026
E.R. Squibb & Sons, L.L.C.AbandonedAbandoned Jun 23, 2026
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by E R Squibb and Sons LLC.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited